MANTECH Publications

Journal of Pharmacovigilance and Quality Assurance
Volume 7, Issue 1, January-June, 2025

Challenges and Solutions in Quality Assurance for Pharmacovigilance in Low-Resource Settings: Strengthening Medicine Safety Surveillance Systems through Practical and Contextual Strategies

Dr. Kavita Pradhan
Assistant Professor
Department of Clinical Pharmacy
Gyanjyoti College of Pharmacy, Bhilwara, Rajasthan
Email id: *kavita.pradhan76@gmail.com*

RajveerTomar
Student
Department of Clinical Pharmacy
Gyanjyoti College of Pharmacy, Bhilwara, Rajasthan
Email id: *rajveer.tomar.qa@yahoo.co.in*

Abstract

Pharmacovigilance plays a pivotal role in ensuring the safety of medicines, especially in low-resource settings where the burden of disease is high, and access to healthcare is limited. However, the implementation of robust quality assurance (QA) systems for pharmacovigilance activities in these settings faces several challenges, including inadequate infrastructure, lack of trained personnel, limited regulatory oversight, and insufficient data collection mechanisms. This paper explores the key challenges hindering effective quality assurance in pharmacovigilance systems in low-resource countries and provides practical, context-specific solutions to address these gaps. Emphasis is placed on the integration of digital technologies, capacity building, policy reform, and stakeholder collaboration to enhance pharmacovigilance practices. By aligning global standards with local realities, low-resource settings can achieve meaningful improvements in drug safety monitoring and public health outcomes.

Keywords:*Pharmacovigilance, Quality Assurance, Low-Resource Settings, Drug Safety, Health Systems Strengthening*

INTRODUCTION

Pharmacovigilance (PV) is the science and activities involved in the detection, assessment, understanding, and prevention of adverse drug reactions (ADRs) or any other drug-related problems. These activities are critical in ensuring that medicines are safe, effective, and monitored for any potential harms. Quality assurance (QA) in pharmacovigilance refers to the processes and systems that guarantee the accuracy, reliability, and consistency of these monitoring activities in alignment with international standards.

In low-resource settings, however, pharmacovigilance systems often suffer from systemic weaknesses due to financial constraints, inadequate infrastructure, and a lack of trained personnel. These challenges significantly undermine the ability of such systems to monitor drug safety effectively, posing risks to public health. This paper examines the specific barriers to implementing quality assurance in pharmacovigilance systems in low-resource settings and proposes practical solutions to address these challenges in a context-specific manner.

LITERATURE REVIEW

Global Standards and Local Realities

The World Health Organization (WHO) and the International Council for Harmonisation (ICH) have developed guidelines aimed at standardizing pharmacovigilance systems worldwide. These guidelines focus on improving ADR reporting, data analysis, and risk management across healthcare systems. However, low-income and lower-middle-income countries often face significant difficulties in meeting these global standards due to various constraints.

High-income countries, with robust regulatory frameworks and advanced technology infrastructure, can integrate automated systems for ADR reporting and analysis. In contrast, many low-resource settings rely on paper-based systems that are prone to errors and inefficiencies. Limited access to technology, poor data management systems, and scarce human resources create an environment where the quality of pharmacovigilance practices is often suboptimal.

Previous Research on Implementation Gaps

Research conducted in various low-income regions, including sub-Saharan Africa, Southeast Asia, and Latin America, highlights key deficiencies in pharmacovigilance infrastructure. These deficiencies include low ADR reporting rates, weak data quality monitoring, and a lack of comprehensive feedback mechanisms for healthcare providers. Studies also emphasize the shortage of trained personnel in pharmacovigilance, the absence of QA frameworks, and the limited awareness among healthcare workers regarding the importance of pharmacovigilance activities.

CHALLENGES IN QUALITY ASSURANCE FOR PHARMACOVIGILANCE

Table no. 1:Common Challenges in Quality Assurance for Pharmacovigilance in Low-Resource Settings

Challenge	Description
Inadequate Infrastructure	Lack of internet, electricity, and digital tools hinders timely ADR reporting.
Limited Human Resources	Shortage of trained PV personnel and overburdened health workers.
Weak Regulatory Oversight	Under-resourced National Regulatory Authorities (NRAs) unable to monitor or enforce QA standards.
Poor Data Quality	Incomplete or inaccurate reports undermine safety signal detection.
Funding Constraints	Insufficient financial support for QA systems and sustainability.

Inadequate Infrastructure

In many low-resource settings, the lack of essential infrastructure—such as internet access, reliable power supply, and digital tools—hinders the ability to collect and report ADRs in a timely and accurate manner. Health facilities in rural and underserved regions may lack the necessary technological tools to implement modern pharmacovigilance practices. This absence of infrastructure creates significant barriers to monitoring the safety of medicines effectively.

Lack of Skilled Personnel

Pharmacovigilance is a highly specialized field that requires skilled personnel to identify, report, and analyze ADRs. However, in low-resource settings, the healthcare workforce is often overburdened with clinical responsibilities. This results in limited time and resources to train staff on pharmacovigilance protocols. Many healthcare providers lack the necessary knowledge and training to properly identify and report ADRs, which further exacerbates the quality assurance challenges.

Weak Regulatory Systems

National regulatory authorities (NRAs) in low-resource settings are often underfunded and understaffed. As a result, they lack the capacity to effectively enforce QA standards, conduct audits, and provide meaningful feedback to healthcare providers and **pharmaceutical** companies. This regulatory weakness contributes to gaps in pharmacovigilance practices and makes it difficult to monitor and control the safety of medicines.

Limited Awareness among Healthcare Workers

Healthcare providers in low-resource settings may not prioritize pharmacovigilance due to a lack of awareness regarding its significance. Many are unaware of the potential dangers of adverse drug reactions and, as a result, fail to report ADRs. Spontaneous reporting, which is the cornerstone of pharmacovigilance, is often overlooked because healthcare workers are unsure of the reporting procedures or do not see the value in reporting adverse effects.

Data Quality and Completeness Issues

In many low-resource settings, pharmacovigilance data is incomplete, inconsistent, or inaccurate. The absence of standardized reporting formats, poor training of healthcare workers, and the lack of systematic quality control checks all contribute to the poor quality of ADR reports. This hampers the ability to detect safety signals and make informed decisions about drug safety.

Funding Constraints

The financial resources required to implement and maintain robust pharmacovigilance systems are often lacking in low-resource settings. Insufficient funding limits the ability to invest in technology, staff training, and infrastructure needed to support quality assurance

efforts. Furthermore, donor dependency may lead to fragmented efforts that do not align with national priorities, further complicating the sustainability of pharmacovigilance systems.

SCOPE OF PHARMACOVIGILANCE IN LOW-RESOURCE SETTINGS

Despite these challenges, pharmacovigilance has significant potential to reduce disease burden and improve health outcomes in low-resource settings:

Potential for Disease Burden Reduction

Adverse drug events (ADEs) are a major public health concern in many low-resource settings. These events are often misclassified as symptoms of other diseases, leading to misdiagnoses and ineffective treatments. By strengthening pharmacovigilance systems, it is possible to detect and address drug-related problems, reducing the overall burden of disease.

Support for Rational Medicine Use

A quality-assured pharmacovigilance system can provide valuable real-world evidence about the safety and efficacy of medicines. This data can help inform treatment guidelines, reduce medication errors, and support antimicrobial stewardship efforts, contributing to better health outcomes.

Integration with Universal Health Coverage (UHC)

The goal of universal health coverage (UHC) is to ensure that all individuals have access to essential health services without financial hardship. Pharmacovigilance systems play a critical role in ensuring that the medicines provided under public health schemes are safe and effective, contributing to the broader goal of UHC.

Contribution to Global Health Security

Strengthening pharmacovigilance at the grassroots level in low-resource settings also enhances global health security. By detecting and reporting adverse drug events early, these systems contribute to the global surveillance of drug-related risks, which is essential for responding to emerging threats and ensuring the safety of medicines worldwide.

PRACTICAL SOLUTIONS TO IMPROVE QUALITY ASSURANCE

Table 2 outlines practical, context-specific solutions to enhance quality assurance in pharmacovigilance in low-resource settings.

Table no: 2

Solution	Implementation Example
Mobile Reporting Tools	Nepal's ADR reporting app for real-time data submission.
Integration into Health Curricula	PV training in nursing and medical schools in East Africa.
Community Health Worker Engagement	Rwanda's use of CHWs in rural ADR surveillance.
SOP Development and QA Audits	Ghana's national SOPs and QA audit visits to facilities.

Capacity Building and Training Programs

Training programs for healthcare workers, regulators, and pharmacists are essential to improving pharmacovigilance practices. These programs should include modules on identifying ADRs, reporting procedures, and conducting risk assessments. Local medical colleges can incorporate pharmacovigilance education into their curricula, ensuring that future healthcare professionals are well-versed in drug safety monitoring.

Use of Mobile and Digital Technologies

Mobile-based ADR reporting tools can help overcome infrastructural challenges in low-resource settings. These tools, such as SMS-based systems, mobile apps, and cloud-based databases, offer cost-effective, scalable solutions for real-time data collection. By leveraging mobile technology, healthcare workers in rural areas can report ADRs promptly, ensuring more timely and accurate data.

Policy Development and Regulatory Strengthening

Governments must prioritize pharmacovigilance in national health policies and allocate adequate resources to strengthen regulatory oversight. By investing in better staffing, training,

and financial support for national regulatory authorities, countries can improve their ability to monitor and enforce pharmacovigilance standards.

Establishment of QA Frameworks and SOPs

Developing and disseminating simple Standard Operating Procedures (SOPs) for ADR reporting and data management can help standardize pharmacovigilance practices across different health facilities. Regular internal audits and quality control checks should be institutionalized to ensure compliance with QA standards and improve data quality.

Community and Patient Engagement

Raising awareness about the importance of pharmacovigilance among patients and caregivers can help improve ADR reporting. Community health workers can also play a key role in pharmacovigilance surveillance, particularly in rural and underserved areas, by actively engaging with local populations and collecting data on ADRs.

International and Regional Collaboration

Participation in international pharmacovigilance networks, such as the WHO Programme for International Drug Monitoring (PIDM) or regional networks like the African Vaccine Regulatory Forum (AVAREF), provides low-resource countries with technical support, training, and access to shared data systems.

CASE EXAMPLES FROM LOW-RESOURCE SETTINGS

Rwanda's Pharmacovigilance System

Rwanda has implemented a robust pharmacovigilance program despite its limited resources. The country has integrated ADR reporting into its electronic health record system, allowing healthcare providers to submit reports more efficiently. Community health workers are also trained to identify and report ADRs, enhancing the country's ability to monitor medicine safety in rural areas.

Nepal's Mobile ADR Reporting Initiative

Nepal introduced a mobile-based ADR reporting app that allows healthcare professionals to submit ADR reports directly to the Department of Drug Administration. This initiative has

significantly improved ADR reporting rates and the quality of data collected, facilitating better decision-making regarding drug safety.

Ghana's QA Audit Program

Ghana's Food and Drugs Authority has implemented periodic QA audits in selected health facilities. These audits have helped improve adherence to standard operating procedures (SOPs) and increased accountability among healthcare providers. Regular QA checks have also enhanced the reliability of ADR data reported from these facilities.

RECOMMENDATIONS FOR STAKEHOLDERS

- Governments should prioritize pharmacovigilance in national health strategies, allocating dedicated funding to enhance capacity and infrastructure.
- Donors and NGOs should align their support with national pharmacovigilance systems to avoid fragmentation and ensure sustainability.
- Academic institutions should develop local expertise through research and training programs in pharmacovigilance.
- Healthcare facilities should appoint designated pharmacovigilance focal points to ensure QA in medicine safety surveillance and foster a culture of drug safety.

CONCLUSION

Quality assurance in pharmacovigilance is essential for safeguarding public health, particularly in low-resource settings where the risks of adverse drug reactions are high. Despite the significant challenges faced by these countries-including inadequate infrastructure, skill shortages, and regulatory weaknesses-there are effective, context-specific solutions available to improve pharmacovigilance practices. By investing in technology, training, regulatory strengthening, and community engagement, low-resource settings can build more robust pharmacovigilance systems that align with global standards and contribute to safer healthcare. A collaborative, adaptive approach will empower frontline health systems to detect and respond effectively to medicine safety issues, ultimately improving public health outcomes globally.

REFERENCES

1. Alhassan, R. K., & Alhassan, M. S. (2017). Pharmacovigilance in resource-poor settings: Challenges and opportunities. International Journal of Health Planning and Management, 32(4), 532-539. https://doi.org/10.1002/hpm.2426
2. Anwar, M. A., &Puri, S. (2020). Strengthening pharmacovigilance in low-income countries: A case study of Pakistan. Pharmacological Reports, 72(3), 542-550. https://doi.org/10.1007/s43440-020-00070-z
3. Aung, K., & Min, T. (2019). Enhancing pharmacovigilance in Southeast Asia: Lessons from Myanmar. Asian Pacific Journal of Tropical Medicine, 12(5), 203-207. https://doi.org/10.4103/1995-7645.259103
4. Bansal, A., & Patel, S. (2018). Role of quality assurance in pharmacovigilance: Perspectives from India. Journal of Pharmaceutical Policy and Practice, 11(1), 3-10. https://doi.org/10.1186/s40545-018-0132-x
5. Chan, E. W., & Cheung, C. S. (2021). Enhancing pharmacovigilance in low-resource countries through mobile technology. Journal of Global Health, 11, 1-10. https://doi.org/10.7189/jogh.11.03011
6. Ghazi, H., & Rehman, S. (2020). Addressing gaps in pharmacovigilance in low-income countries: A systematic review. Pharmaceutical Regulatory Affairs, 9(2), 15-20. https://doi.org/10.1016/j.jpharm.2020.05.003
7. Global Health Workforce Alliance. (2018). Strengthening the pharmacovigilance workforce in low-resource settings. World Health Organization. Retrieved from https://www.who.int/hrh/resources/pharmacovigilance-workforce
8. Khan, A. H., & Abid, F. (2019). Quality assurance in pharmacovigilance: Challenges in Pakistan. Journal of Clinical Pharmacology, 59(6), 721-728. https://doi.org/10.1002/jcph.1384
9. Kato, T., & Yamagata, H. (2017). Evaluating the effectiveness of community health workers in pharmacovigilance: A case study from Rwanda. Public Health Research, 5(1), 23-30. https://doi.org/10.1080/21622348.2017.1370380
10. World Health Organization. (2019). Pharmacovigilance: Ensuring drug safety in low-income countries. World Health Organization. Retrieved from https://www.who.int/pharmacovigilance/en/

11. Lall, R., & Goyal, R. (2018). Integrating pharmacovigilance into medical curricula in low-resource settings. Journal of Medical Education, 49(1), 54-60. https://doi.org/10.1111/medu.13501
12. Lee, A., & Tan, J. (2018). Challenges and solutions in pharmacovigilance in Southeast Asia. Asian Journal of Pharmaceutical Sciences, 13(4), 254-262. https://doi.org/10.1016/j.ajps.2018.05.003
13. Mwai, M., & Mwangi, P. (2021). Mobile solutions for pharmacovigilance in Kenya: An evaluation of an SMS-based ADR reporting system. BMC Health Services Research, 21(1), 401. https://doi.org/10.1186/s12913-021-06487-2
14. Oyedepo, A., &Olayemi, O. (2017). Strengthening regulatory frameworks for pharmacovigilance in Africa: A systematic approach. African Journal of Pharmacy and Pharmacology, 11(6), 72-80. https://doi.org/10.5897/AJPP2016.4517
15. Pires, J., & Barbosa, D. (2019). Quality assurance frameworks for pharmacovigilance: Insights from Brazil's national pharmacovigilance program. International Journal of Environmental Research and Public Health, 16(18), 3441. https://doi.org/10.3390/ijerph16183441
16. Rao, A. P., & Mishra, A. (2020). Capacity building for pharmacovigilance: A model for developing countries. Global Health Action, 13(1), 10-17. https://doi.org/10.1080/16549716.2020.1803461
17. Siddiqui, N., &Kiani, R. (2020). Pharmacovigilance system in low-resource countries: Challenges and future directions. Journal of Drug Safety, 43(4), 287-294. https://doi.org/10.1007/s13181-019-00784-3
18. Tomic, M., &Husein, S. (2021). Addressing challenges in pharmacovigilance through international collaboration. Pharmaceutical Policy and Practice, 12(3), 56-63. https://doi.org/10.1186/s40545-021-00305-w
19. World Health Organization. (2020). World Health Organization pharmacovigilance guidelines. WHO Technical Report Series. Retrieved from https://www.who.int/publications/2019/WHO-TRS-pharmacovigilance
20. Yadav, R., & Kumar, A. (2021). Empowering community health workers for pharmacovigilance in rural India: A successful model. Global Health Action, 14(1), 1900-1907. https://doi.org/10.1080/16549716.2021.1899000